BlackRock Health Sciences Opportunities Portfolio Class K
SHSKX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 1 University Square Drive, 5th Floor Princeton NJ United States of America 08540
- IPO Date
- Jun 13, 2016
- CIK
- 0001821693
- Website
- blackrock.com
- Similar Companies
- Business
- BlackRock Health Sciences Opportunities Portfolio Class K (SHSKX) is an open-end mutual fund that seeks long-term growth of capital primarily through investment in equity securities of companies in health sciences and related industries. The fund normally invests at least 80% of its total assets in equity securities, primarily common stocks, concentrated in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals; it may also invest in companies located in non-U.S. countries, with approximately 93% of assets in U.S. stocks, 4% in non-U.S. stocks, and the remainder in cash and other assets as of late 2025. Top holdings include Eli Lilly and Company (8.5%), Johnson & Johnson (8.3%), Abbott Laboratories (5.3%), AbbVie Inc. (4.2%), and UnitedHealth Group Inc. (4.1%), representing about 30% of the portfolio; the fund maintains a diversified portfolio of around 148 holdings primarily in the healthcare sector (96%). Managed by BlackRock Fund Advisors since the inception of the broader fund in 1999 and the Class K shares launched on June 8, 2016, the fund is domiciled in the United States with headquarters in New York, New York, targets institutional investors with a minimum initial investment of $5 million, and features a net expense ratio of 0.75%. The fund is co-managed by Erin Xie, PhD, who has led the portfolio since July 31, 2003, and Xiang Liu, PhD, who joined as co-manager on June 1, 2020, leveraging scientific expertise to focus on innovative healthcare equities with diversified returns and lower volatility relative to benchmarks like the Russell 3000 Healthcare Index. Geographically, operations emphasize U.S. markets (93% allocation) with minor exposure to Europe, the United Kingdom, the Middle East, and the Eurozone. In recent developments, the fund issued its annual shareholder report for the period ended May 31, 2025, highlighting strong contributions from holdings such as Boston Scientific Corp., Abbott Laboratories, and Gilead Sciences, Inc., driven by robust revenue growth, earnings beats, and positive guidance in medical devices, diagnostics, and biotech segments. Portfolio characteristics as of September 30, 2025, reflect a forward P/E ratio of 19.92x, P/B ratio of 4.98x, active share of 31.05%, and three-year alpha of 0.15, underscoring a value-oriented large-cap approach within health sciences. No major acquisitions, partnerships, funding rounds, or strategic shifts specific to the fund were reported in the last 1-2 years, with management and investment policy remaining stable under BlackRock's Active Equity Group.